Impulso.Space USA Corp. Secures Contract to Provide Integrated Launch Services to Relativity Space Inc.
Impulso.Space USA Corp., a leading provider of integrated end-to-end launch services, proudly announces the signing of a significant contract with Relativity Space Inc. This landmark agreement solidifies Impulso.Space’s position as a key player in the aerospace industry and underscores its commitment to providing comprehensive global launch solutions for upcoming satellite constellations requiring highly responsive and affordable services.
Under the terms of contract, Impulso.Space will deliver a range of logistical and operational services to support launch campaigns and related activities for the upcoming missions of the launch operator in question. Leveraging its state-of-the-art facilities in Florida, Impulso.Space will play a pivotal role in ensuring the success of each mission — from pre-launch preparations to post-launch operations.
"We are thrilled to partner with Relativity Space and provide them with our expertise in integrated logistics and operational services, as well as our brokerage of launch capacity," said Pietro Guerrieri, CEO of Impulso.Space. "This partnership exemplifies our dedication to offering seamless, integrated solutions that meet the unique needs of our clients and propel the rapid growth of future launch services. We are confident that our partnership with Relativity Space will yield exceptional results and pave the way for new opportunities in the space industry."
Impulso.Space services include payload integration, launch vehicle processing, mission management, shipment, and other operational services. With a proven track record of success and a continuous commitment to innovation, Impulso.Space stands ready to support the entire value chain of launch services and facilitate execution to final users.
As Impulso.Space continues to expand its capabilities and forge strategic partnerships, it further solidifies its spot at the forefront of the global space sector, driving progress and shaping the future of global, integrated solutions for launch services.
For more information about Impulso.Space and its integrated launch services, please visit https://impulso.space.
About Impulso.Space
Impulso.Space is a leading provider of integrated end-to-end launch services, offering turnkey solutions for global and seamless launch services. With state-of-the-art facilities and a commitment to excellence, Impulso.Space is dedicated to driving innovation and advancing the boundaries of global space services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402954237/en/
Contact information
Impulso.Space USA Corporation
Ascanio Montemaggi, Head of Communication
ascanio@impulso.space
https://impulso.space
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kweichow Moutai’s Brand Culture Activities in Greece Foster Sino-Greek Cultural Cooperation21.12.2024 19:41:00 CET | Press Release
On December 9th, the exhibition “Longevity in the Tao of Chrysanthemum: The Artistic World of Qi Baishi,” supported by Kweichow Moutai Group, opened at the Athens University History Museum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241221429801/en/ Gao Shan(R3), and Petros Tatoulis(R2), took a group photo with other guests at the opening ceremony of the exhibition. (Photo: Business Wire) Featuring the works of Qi Baishi, a renowned Chinese painter, the exhibition highlights the unique charm of traditional Chinese culture for Western audiences, while advancing cultural exchange and mutual understanding between China and Greece. Gao Shan, Chairman of the Labor Union at Kweichow Moutai Distillery (Group) Co., Ltd., remarked on the significance of the event, saying, “Qi Baishi employed distinctive Eastern painting techniques to convey the Chinese perspective of the world. Athens, a city celebrated for its great masters and
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom